Potential Targets and Plausible Drugs of Coronavirus Infection Caused by 2019-nCoV

A 2020 review paper from the University of Tehran discusses potential molecular targets for drug development against the novel coronavirus. The paper overviews current drugs in the pipeline and highlights protease and RNA polymerase as promising targets. Based on antiviral repurposing and clinical studies, it suggests remdesivir as an encouraging frontline treatment.

Use Cases

• Identifying promising antiviral targets for 2019-nCoV based on the discussion of the viral life cycle.
• Reviewing plausible drug candidates for repurposing against COVID-19 as overviewed in the paper.
• Comparing the efficacy of different drug target types, such as protease versus RNA polymerase, for coronavirus drug screening.

Strengths

• Focuses on specific, promising molecular targets like protease and RNA polymerase for drug screening.
• Provides a discussion of the drug life cycle and potential targets based on the state of knowledge in early 2020.
• Identifies a specific candidate drug, remdesivir, based on repurposing and clinical study results.

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download.
• Row count and file formats are unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.

Provenance

Source

University of Tehran

Collection Method

Academic review paper.

Time Range

Early 2020 (context of the 2019-nCoV/COVID-19 pandemic).